When was Kite Pharma founded?

Kite Pharma was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Where is Kite Pharma located?

Kite Pharma is headquartered in Los Angeles, United States. It is registered at Ventspils, Fabrikas iela 8A.

How many employees does Kite Pharma have?

As of Jul 31, 2026, the latest employee count at Kite Pharma is 4053.

Is Kite Pharma a funded company?

Kite Pharma is a funded company, having raised a total of $97.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 09, 2011.

When was the latest funding round of Kite Pharma?

Kite Pharma's latest funding was a $***** Post IPO round on Apr 03, 2018, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.97B in funding in 2026 to date.

What is the annual revenue of Kite Pharma?

Annual revenue of Kite Pharma is between $100M and $500M as on Dec 31, 2024

Where does Kite Pharma rank among its competitors?

Kite Pharma ranks 29th amongst 3388 active competitors, of which 1144 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kite Pharma?

Kite Pharma's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kite Pharma - 2026 Company Profile, Funding, Competitors & Financials

Q: Is Kite Pharma an acquired company?

Kite Pharma got acquired by Gilead on Aug 25, 2017.

Kite Pharma is an acquired company based in Los Angeles (United States), founded in 2009. It operates as a Developer of cancer immunotherapy products using genetic engineering. Kite Pharma has raised $97.7M in funding from Alta Partners. The company has 3388 active competitors, including 1144 funded and 805 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of cancer immunotherapy products using genetic engineering. The company's product Yescarta a CAR-T therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma and TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Website: www.kitepharma.com/
Social
Registered Address: Ventspils, Fabrikas iela 8A

Key Metrics

Founded Year

2009

Location

Los Angeles, United States

Stage

Acquired

Total Funding

$97.7M in 7 rounds

Latest Funding Round

Post IPO, Apr 03, 2018, $*****

Investors

Alta Partners & 11 more

Ranked

29^th among 3388 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2024

Employee Count

4,053 as on Jul 31, 2026

Investment & Acquisitions

Aspen Neuroscience & 10 more

Similar Companies

Senti Bio & 403 more

Exit Details

Acquired by Gilead (Aug 25, 2017)

View Kite Pharma's full profile

Kite Pharma is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kite CIN: 50003976981 , Latvia, Active	Dec 11, 2007	€0 - €1M (As on Dec 31, 2024)	1 (As on Dec 31, 2022)	-
Gilead Sciences, Inc. CIN: 943047598 , United States, Active	Dec 31, 2008	$100M - $500M (As on Dec 31, 2024)	10903 (As on Dec 31, 2024)	-
Kite Pharma, Inc. CIN: 1510580 , United States, Active	May 31, 2009	$10M - $50M (As on Dec 31, 2016)	674 (As on Dec 31, 2018)	-
Kite Pharma, Inc. CIN: 693423 , United States, Active	Dec 02, 2021	-	-	-

Kite Pharma got acquired by Gilead on Aug 25, 2017 at an acquisition amount of $*****.

Click here to take a look at Kite Pharma's acquisition in detail

Kite Pharma has raised a total funding of $97.7M over 7 rounds. Its first funding round was on Mar 09, 2011. Kite Pharma has 10 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Kite Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2018	6275017	Post IPO	5804576	7305326	5278888	4916550
Jan 05, 2015	1865685	Post IPO	5902954	6565657	8066319	Amgen Business Development
Dec 2014	9851568	Post IPO	8127265	6829420	2009027	4938182

Access funding benchmarks and valuations. Sign up today!

View details of Kite Pharma's funding rounds and investors

Kite Pharma's employee count trend

Kite Pharma has 4,053 employees as of Jul 26. Here is Kite Pharma's employee count trend over the years:

Uncover Kite Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kite Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kite Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
29th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Amgen Business Development, BB Biotech & 10 others	67/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Kite Pharma's competitors? Click here to see the top ones

Kite Pharma has made 8 investments in companies including Aspen Neuroscience and Ensoma. Kite Pharma has also acquired 3 companies including Interius Biotherapeutics and Tmunity Therapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Nov 20, 2025	Investments	Aspen Neuroscience	2018	San Diego (United States)
Aug 21, 2025	Acquisition	Interius Biotherapeutics	2020	Philadelphia (United States)
May 16, 2023	Investments	Ensoma	2019	Boston (United States)